Abstract

BackgroundTo investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil.MethodsA retrospective study was conducted on 61 patients with severe left heart valvular disease combined with moderate or severe PAH who had undergone mechanical mitral and/or aortic valve replacement from April 2018 to October 2018. The patients were divided into the treprostinil group and the conventional treatment group according to whether they received treprostinil. The patients were assessed by SwanGanz catheterization, echocardiography, the 6-min walk test (6-MWT), the Borg dyspnoea score and the SF-36 questionnaire.ResultsCompared with the preoperative data, the mPAP measured by SwanGanz catheterization, the results of the 6-MWT and the Borg score were significantly improved in both groups during the 1 year follow-up (P < 0.05). Regarding the comparison between the groups, the results in group T were significantly better than those in group C, including the results of the 6-MWT and the general health, vitality and mental health of SF-36 during the 1 year follow-up (P < 0.05).ConclusionsContinuous subcutaneous infusion of treprostinil was not capable of decreasing pulmonary pressures in patients with severe left heart valvular disease combined with moderate or severe PAH during 1 year follow-up, although which some of our data suggest that might improve the symptoms and quality of life of these patients.

Highlights

  • To investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil

  • This retrospective study mainly discussed the midterm postoperative prognosis of patients with severe left heart valvular disease combined with PAH who were treated with subcutaneous injection of treprostinil

  • Moderate or severe PAH was diagnosed in these patients based on the following criteria: pulmonary artery systolic pressure (PASP) > 50 mmHg estimated by transthoracic echocardiography (TTE) and the mean pulmonary artery pressure > 35 mmHg measured by SwanGanz catheterization [11]

Read more

Summary

Introduction

To investigate the midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension (PAH) using subcutaneous injection of treprostinil. Based on a literature search, few studies exist on the use of treprostinil in patients with PAH caused by left heart valve disease. This retrospective study mainly discussed the midterm postoperative prognosis of patients with severe left heart valvular disease combined with PAH who were treated with subcutaneous injection of treprostinil

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call